Age
Item
1. age: older than 20
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
2. eastern cooperative oncology group (ecog) performance status 0 -2
boolean
C1520224 (UMLS CUI [1])
Malignant neoplasm of lung | Pancreatic carcinoma | Malignant tumor of colon
Item
3. histologically confirmed lung cancer, pancreatic cancer, or colon cancer
boolean
C0242379 (UMLS CUI [1])
C0235974 (UMLS CUI [2])
C0007102 (UMLS CUI [3])
Epidermal growth factor receptor inhibitor
Item
4. patients take egfr inhibitor following the reason
boolean
C1443775 (UMLS CUI [1])
EGFR gene mutation Non-Small Cell Lung Carcinoma | Adenocarcinoma First line treatment
Item
egfr mutation (+) nsclc - adenocarcinoma for 1st line treatment
boolean
C3266992 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0001418 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
Non-Small Cell Lung Carcinoma | Second line treatment
Item
nsclc - for ≥ 2nd line treatment
boolean
C0007131 (UMLS CUI [1])
C1710038 (UMLS CUI [2])
Pancreatic carcinoma | Adenocarcinoma First line treatment gemcitabine
Item
pancreatic cancer - adenocarcinoma for 1st line treatment with gemcitabine
boolean
C0235974 (UMLS CUI [1])
C0001418 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0045093 (UMLS CUI [2,3])
Malignant tumor of colon | Adenocarcinoma First line treatment irinotecan Folinic Acid-Fluorouracil-Irinotecan Regimen
Item
colon cancer - adenocarcinoma 1st line treatment with irinotecan (folfiri)
boolean
C0007102 (UMLS CUI [1])
C0001418 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0123931 (UMLS CUI [2,3])
C1880658 (UMLS CUI [2,4])
Skin side effects Due to Epidermal growth factor receptor inhibitor
Item
5. patients who have egfr inhibitor related skin side effects (erse) gr≥2 (ncictc v4.0)
boolean
C1123023 (UMLS CUI [1,1])
C0879626 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C1443775 (UMLS CUI [1,4])
Compliance behavior Study Protocol
Item
6. a patient with the willingness to comply with the study protocol during the study period and capable of complying with it
boolean
C1321605 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Informed consent | Study Subject Participation Status
Item
7. a patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages
boolean
C0021430 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Prior Immunotherapy
Item
1. a patient with previous active or passive immunotherapy
boolean
C1514461 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
2. a pregnant or lactating patient
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Childbearing Potential | Pregnancy test positive Absent | Postmenopausal state | Amenorrhea Period
Item
3. a patient of childbearing potential without being tested for pregnancy at baseline for positive. (a postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)
boolean
C3831118 (UMLS CUI [1])
C0240802 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0232970 (UMLS CUI [3])
C0002453 (UMLS CUI [4,1])
C1948053 (UMLS CUI [4,2])
Seizures Uncontrolled | CNS disorder | Mental disorders | Informed Consent Unable | Compliance behavior Limited
Item
4. a patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications
boolean
C0036572 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0007682 (UMLS CUI [2])
C0004936 (UMLS CUI [3])
C0021430 (UMLS CUI [4,1])
C1299582 (UMLS CUI [4,2])
C1321605 (UMLS CUI [5,1])
C0439801 (UMLS CUI [5,2])
Care Dermatologic | Urticaria Transient
Item
5. a patient with history of dermatologic care (except transient urticaria) within 4 weeks
boolean
C1947933 (UMLS CUI [1,1])
C0205489 (UMLS CUI [1,2])
C0042109 (UMLS CUI [2,1])
C0205374 (UMLS CUI [2,2])
Heart Diseases | Congestive heart failure | Coronary Artery Disease Symptomatic | Cardiac Arrhythmia | Myocardial Infarction
Item
6. a patient with clinically significant (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmias, etc) or myocardial infarction within past 12 months
boolean
C0018799 (UMLS CUI [1])
C0018802 (UMLS CUI [2])
C1956346 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0003811 (UMLS CUI [4])
C0027051 (UMLS CUI [5])
Pneumonia, Interstitial | Pulmonary Fibrosis Diffused Symptomatic
Item
7. a patient with interstitial pneumonia or diffused symptomatic fibrosis of the lungs.
boolean
C0206061 (UMLS CUI [1])
C0034069 (UMLS CUI [2,1])
C0012222 (UMLS CUI [2,2])
C0231220 (UMLS CUI [2,3])
Transplantation, Homologous | Therapeutic immunosuppression
Item
8. organ allogenic transplantation requiring immunosuppressive therapy. any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by case basis prior to enrolling the subject
boolean
C0040739 (UMLS CUI [1])
C0021079 (UMLS CUI [2])
Hypersensitivity Investigational New Drugs | intolerance to Investigational New Drugs | Hypersensitivity Chemotherapy Pharmaceutical Preparations | intolerance to Chemotherapy Pharmaceutical Preparations
Item
9. known allergies, hypersensitivity, or intolerance to study drugs, chemotherapy drugs using this clinical trial
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C0013227 (UMLS CUI [3,3])
C1744706 (UMLS CUI [4,1])
C0392920 (UMLS CUI [4,2])
C0013227 (UMLS CUI [4,3])